In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICEATM

This article was originally published in The Rose Sheet

Executive Summary

No public comments were received on the "Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays," the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods states in a Sept. 28 Federal Register 1notice. The document is available on the NICEATM Web site. NTP had requested comments on the addendum when it was published in a March 16 Federal Register notice. The addendum proposed replacing four substances from a list proposed for validation of the screening methods (2"The Rose Sheet" March 20, 2006, In Brief)...

You may also be interested in...



ICCVAM

Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays published in a March 16 Federal Register notice includes recommendation by Interagency Coordinating Committee on the Validation of Alternative Methods to replace four substances that are not commercially available or have restricted availability - anastrazole, CGS 18320B, fadrozole and ICI 182,780 - with 4-hydroxyandrostenedione, chrysin, dicofol and raloxifene HCl. ICCVAM published final report containing minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays in 2003 (1"The Rose Sheet" June 16, 2003, In Brief). Comments on addendum, which also identifies six other substances that could be replaced, are due May 1...

Italy Opens Up On Trial Woes In A Pandemic

Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy. 

KKR Deal To Bolster JB Chemicals’ Expansion Efforts

US private equity firm KKR to acquire a majority stake in JB Chemicals, accelerating the Indian group's growth plans in branded formulations. Post a 54% stake acquisition for $414m via part-purchase from the founders and an open offer at INR 745/share, the PE's final stake could go up to 64.9% if founders offer more shares

UsernamePublicRestriction

Register

SC027412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel